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Summary  I examined whether two or more distinct amine oxidases exist in monkey platelets. Km values of amine 
oxidase in monkey platelets were determined with benzylamine as substrate from the Lineweaver-Burk double 
reciprocal plots. Two Km values, 100 and 1.38 M at high and low benzylamines, respectively, were obtained. 
When the enzyme in platelets was preincubated at 37 ˚C for 40 min with clorgyline and deprenyl, the deamination of 
1 M benzylamine was not inhibited at high concentrations of these inhibitors, while it was highly sensitive toward 
semicarbazide. When corresponding experiments were performed with 100 M benzylamine, opposite results were 
obtained. Inhibition of semicarbazide-sensitive amine oxidase (SSAO; EC 1.4.3.6) was not infl uenced by varying 
the time of incubation of the enzyme with semicarbazide, indicating direct and reversible inhibition of SSAO. These 
data might suggest the existence of not only monoamine oxidase (MAO; EC 1.4.3.4) but also SSAO in monkey 
platelets. The mode of inhibition of SSAO was reversible. The most potent inhibition of SSAO was observed with 
imipramine, followed by maprotiline, zimeldine and nomifensine. The mode of inhibition of SSAO was reversible. 
Tricyclic antidepressant drugs were most selective inhibitors of SSAO activity in monkey platelets, as compared 
with other types of antidepressant drugs.
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Introduction
Semicarbazide-sensitive amine oxidase (SSAO; EC 
1.4.3.6) exists in plasma membranes of various tissues and 
blood plasma1). SSAO differs from monoamine oxidase 
(MAO; EC 1.4.3.4) and deaminates various xenobiotic 
amines in mammalian tissues2). SSAO is often characterized 
by its relatively high activity toward benzylamine, which 
is also metabolized by MAO. However, the affinity of 
SSAO toward benzylamine is considerably higher than 
that of MAO1). Despite its widespread tissue distribution, 
physiological roles of SSAO remain far from clear3). MAO 
was classified into two forms, MAO-A and MAO-B, on 
the basis of their different sensitivities to inhibition by 
the selective MAO inhibitors, clorgyline and depreny4). 
In addition, platelet amine oxidase activities in affective 
disorders such as schizophrenia have been described5). 
However, there are few studies on possible physiological 
relationships between platelet amine oxidase activity and 
psychiatric diagnosis. I have previously reported6) that 
MAO-B in monkey platelets differ from MAO-B in the 
liver and that it exists in multiple forms. The isoenzymic 
pattern in diseases7) may differ from normal. Therefore, it is 
considered necessary to investigate the enzymic properties 
of platelet amine oxidase. I examined whether there might 
two or more distinct isoenzymes of amine oxidase in 
monkey platelets. On the other hand, various antidepressant 
drugs have been developed, and their antidepressive effects 
have been observed in animal models8)-10). Antidepressant 
drugs have heretofore been considered effective in the 
treatment of depression11),12). However, relationships 
between SSAO and antidepressants are obscure13). Platelet 
MAO activities in affective diseases such as schizophrenia 
have been described14). There are few studies on a possible 
physiological relationship between platelet MAO and 
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psychiatric diagnosis15). Thus, it is important to investigate 
enzymic properties of platelet SSAO. Therefore, I examined 
whether other cyclic or noncyclic antidepressants inhibit 
monkey platelet SSAO activity.
Experimental
Drugs and chemicals
The MAO inhibitors clorgyline and deprenyl16) and the 
amine oxidase inhibitor, semicarbazide hydrochloride, were 
obtained from Sigma Chemical Co. Ltd., St. Louis, MO., 
USA. The following drugs used in the study were donated 
by each manufacture: zimeldine hydrochloride (Fujisawa, 
Osaka, Japan), imipramine and maprotiline hydrochloride 
(Chiba-Geigy, Takarazuka, Japan), nomifensine maleate 
(Hoechst, Frankfurt, Germany). All other chemicals were 
obtained from Wako Pure Chemical Industries (Osaka, 
Japan). The radioactive substrate [7-14C]-benzylamine 
hydrochloride (1.85-2.29 Gbq/mmol) was obtained from 
Habersham International (Habersham, England).
Monkey platelet preparations
Japanese monkeys (Malacca furcate ,  male 3- to 
6-year-old, n=5) were donated by Animal Center, Oita 
Medical University. This study was approved by the 
Ethical Committee for Animal Experiments, Oita Medical 
University, Japan. Blood was quickly removed under 
chloral hydrate (400 mg/kg i.p.) anesthesia. After sodium 
citrate anticoagulant (3.8% or 0.12 M) was added to the 
sample, the blood was centrifuged at 1,100 p.m. for 10 
min to remove red cells, and then the supernatant was 
centrifuged at 3,000 g for 30 min. The pellet containing 
platelets was suspended in 10 volumes of 0.01 M 
potassium phosphate buffer (pH7.4) and used as the 
enzyme preparation. Protein concentrations of the enzyme 
preparation were measured according to the method of 
Lowry et al.17) using the standard of bovine serum albumin.  
Assay of SSAO activity
The SSAO activity was measured using the labelled 
substrates [14C]-benzyl amine, as described previously18). 
The reaction was started by adding the labelled substrate, 
and the mixture was incubated for 20 min at 25˚C. The 
reaction was then stopped by adding hydrochloric acid 
(2N). The products of the reaction were extracted with 2 ml 
of benzene-ethyl acetate (1:1, V/V) saturated with water. 
Triton X-100 toluene scintillation liquid (10 ml) was added 
to 1.0 ml samples of the extract, and the radioactivity was 
measured in a Beckman LS-9000 scintillation spectrometer. 
All values are presented as means±S.E.M. In inhibition 
studies, enzyme preparations were preincubated with 
various concentrations of semicarbazide for 40 min at 37 
˚C before adding [14C]-benzylamine for the assay of the 
remaining amine oxidase activity. For investigating the 
effects of these antidepressant drugs on SSAO activity in 
vitro, the enzyme was preincubated for 20 min at 25 ˚C 
with antidepressants of concentrations of 1.0 mM from 
to 1.0 M before adding the substrate. In all cases, product 
formation was linear with the protein amount and with time 
periods of incubation used. 
Results
The Km values of amine oxidase in monkey platelets 
with benzylamine used as substrate were determined from 
the Lineweaver-Burk double reciprocal plots shown in 
Fig.1. 
Figure 1
Linewearer-Burk double reciprocal plots of benzylamine deamination 
by monkey platelets.
 Linewear-Burk plots of initial velocity of benzylamine oxidation 
against benzylamine concentrations were prepared. The enzyme 
activity was assayed radiochemically by addition of the benzylamine 
concentration. Two Km values of a high benzylamine concentration 
(100M) and a low benzylamine concentration (1.38M) were 
obtained. Abscissa: reciprocal of substrate concentration in mM. 
Ordinate: reciprocal of the initial velocity of the enzyme reaction. 
Values are means±S.E.M. for fi ve animals.
Two Km values 1.38 and 100 M, at low and high 
benzylamine concentrations, respectively. in monkey 
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platelet  were obtained.  When the platelets  were 
preincubated at 25˚C for 20 min with clorgyline and 
deprenyl, the deamination of 1 M benzylamine by SSAO 
activity was not inhibited at high concentrations of these 
inhibitors, while it was inhibited by low concentrations 
of semicarbazide, the inhibition complete at 10-4 M 
semicarbazide (Fig.2A). 
Figure 2
Inhibition of benzylamine deamination in monkey platelets by 
clorgyline, deprenyl and semicarbazide at 1M and 100M 
benzylamine as substrate.
 The enzyme preparation was preincubated with clorgyline (open 
circle), deprenyl (closed circle) and semicarbazide (triangle). Enzyme 
activity were assayed radiochemical by addition of 1M benzylamine 
at 25 ˚C for 20 min for SSAO activity (A) and 100M benzylamine 
at 37 ˚C for 40 min.for MAO activity (B). The remaining activity was 
expressed as percentage of the control activity. Values are means±S.
E.M. for fi ve animals.
Corresponding experiments performed with 100 M 
benzylamine at 37 ˚C for 40 min gave opposite results. 
Deamination of 100 M benzylamine was highly sensitive 
toward clorgyline and deprenyl, while it was less sensitive 
toward semicarbazide as compared with the deamination 
of of 1 M benzylamine (Fig.2B). Inhibitory actions of 
various antidepressant drugs are shown in Fig.3. The time-
course of inhibition of SSAO by semicarbazide indicated 
that the extents of inhibition did not change even for the 
period of preincubation time up to 60 min at 25 ˚C (Table 1). 
This may indicate that semicarbazide is a reversible 
inhibitor of SSAO in monkey platelets, and that the mode 
of inhibition is noncompetitive. This enzyme differs 
from MAO and deaminates various monoamines. All the 
results presented strongly indicate that the mechanism for 
inhibition of SSAO by semicarbazide in vitro is certainly 
different from that of MAO-B. These data might indicate 
not only the existence of MAO, but also SSAO in monkey 
platelets. Although the physiological role of SSAO is 
unknown, the biological signifi cance of this observation is 
apparent. All four antidepressants inhibit SSAO activity in 
a concentration-dependent manner. The residual activities 
of SSAO were about 85.3%, 76.9%, 69.3%, and 16.3% 
at 100 M of nomifensine, zimeldzine, maprotililine and 
imipramine, respectively (Fig.3). 
Figure 3
Inhibition of SSAO activity by various antidepressant drugs in monkey 
platelet.
After incubation at 25 ˚C for 20 min at various concentrations of 
antidepressant drugs, SSAO activity was determined with 1M 
benzylamine as substrate at 37 ˚C for 20 min. Values are expressed 
as percent of control. The results are means±S.E.M. for six animals; 
closed circle, nomifensine; open circle, zimeldine, triangle, 
imipramine; square, maprotiline. Values are means±S.E.M. for six 
animals.
Discussion
The existence of at least two forms of MAO2), named 
A-form MAO and B-form MAO, was first demonstrated 
by Johston22). A-form MAO preferentially deaminates 
5-hydroxytryptamine, whereas B-form MAO deaminates 
-phenylethylamine23). However, benzylamine is the best 
substrate so far examined for SSAO1), 2). It seems likely that 
total benzylamine deamination at the assay concentration 
may be mainly due to the difference in the Km values of 
SSAO (around 5 M)20) and MAO (around 160 M)21) 
for this substrate. Consequently, low benzylamine 
16 Toshio OBATA
concentrations can be used for studying benzylamine 
deamination by SSAO alone that may be present. 
Discrimination between MAO and SSAO on the basis of 
substrate concentration was only possible by using 1 M 
benzylamine for the assay concentration. In the present 
work, the data without the MAO inhibitor pretreatment 
indicated that benzylamine deamination was predominantly 
by SSAO at the substrate concentration (1 M) used. In 
monkey platelets, 1 M benzylamine was deaminated 
solely by SSAO. The time-course of inhibition of SSAO by 
semicarbazide indicated that the degree extents of inhibition 
did not change even for a preincubation time up to 60 min 
at 25 ˚C (Table 1). 
Table 1
Effect of preincubation time with semicarbazide on semicarbazide-
sensitive amine oxidase (SSAO) in monkey platelet.
Monkey platelets were preincubated with semicarbazide at various 
concentration at 37 ˚C for the indicated times, and then remaining 
SSAO activity was assayed, as described in the text. Values 
were expressed as percent inhibition of SSAO activity with 1M 
benzylamine as substrate in preparations preincubated with water for 
the same periods. Values are means±S.E.M. for fi ve animals.
This may indicate that semicarbazide is a reversible 
inhibitor of SSAO in monkey platelets, and that the mode 
of inhibition is noncompetitive. This enzyme differs from 
MAO in that it and deaminates various monoamines. All 
results presented strongly indicate that the mechanism for 
inhibition of SSAO by semicarbazide in vitro is certainly 
different from that of MAO-B. These data might indicate 
the existence of not only MAO but also SSAO in monkey 
platelets. Although the physiological role of SSAO is 
unknown, the biological significance of this observation 
may be important.
 There are many studies on the relationship between the 
antidepressant and MAO-inhibiting actions24)-26). However, 
it is not clear how SSAO inhibition by these antidepressants 
occurs in platelets. When monkey platelets were used 
as the enzyme preparation, greatest SSAO inhibition 
was obtained by tricyclic drug imipramine, followed by 
tetracyclic maprotiline, dicyclic zimeldine and non-cyclic 
drug nomifensine. The time-courses of inhibition of SSAO 
by various antidepressant drugs showed that the extent 
of inhibition did not change over the preincubation time 
up to 60 min at 25 ˚C (data not shown), indicating these 
antidepressant drugs to be reversible SSAO inhibitor in 
monkey platelets. This may be related to differences in 
the chemical structures (dicyclic, tricyclic, tetracyclic 
and noncyclic) 27) or differences in the binding sites for 
these antidepressants in the particular animal species 
used in the present experiments. It is considered that the 
differences in the sensitivity of monkey platelet SSAO to 
these antidepressants may exist due to multiple catalytic 
sites. These antidepressant drugs were found to be selective 
SSAO inhibitors in monkey platelets. Further studies 
are necessary to determine whether or not those effects 
are important with regard to the pharmacologic action 
of antidepressant drugs. The results of the present study 
may be useful in elucidating the actual mechanism of the 
physiological function of SSAO in platelets.
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サル血小板中に存在するセミカルバザイドアミン酸化酵素（SSAO）の各種
抗うつ剤による阻害




サル血小板中のアミン酸化酵素のKm 値を Lineweaver-Burk二重逆数プロット法より求めた。それぞれ高（100 M）
と低（1.381M）濃度の親和性の異なる 2 つの Km値が得られた。1Mベンジルアミンを基質として、血小板中
の酵素をクロルジリンおよびデプレニルで 37 ℃で 40 分間プレインキュベーションしたところ、高濃度でも阻害
されないが、セミカルバザイドでは高い感受性を示した。相当する実験を 100 M ベンジルアミンを基質として
行ったところ、反対の結果が得られた。セミカルバザイドアミン酸化酵素（SSAO）活性はセミカルバザイドで
インキュベーションの時間を変えても SSAO活性は変化しなかったことより可逆的阻害であることが示された。
これらのデータよりサル血小板中にはモノアミン酸化酵素（MAO）だけでなく SSAOもまた存在することを示
している。その阻害は可逆的であった。SSAO活性に対してはイミプラミンが最も強く、次にマプロチリン、ジ
メルジン、ノミフェンシンの順で可逆的であった。三環系抗うつ剤はサル血小板 SSAO活性に対しては他の抗う
つ剤と比べると、最も選択的な阻害剤であった。
キーワード：セミカルバザイドアミン酸化酵素（SSAO）、モノアミン酸化酵素（MAO）、抗うつ薬、ベンジルアミン、
サル血小板
